ExodusPoint Capital Management’s ADC Therapeutics ADCT Stock Holding History

ExodusPoint Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$72.3K	Sell	19,280 -37,503	-66%	-$148K	﹤0.01%	1452
2025 Q4	$200K	Buy	56,783 +10,842	+24%	+$44K	﹤0.01%	1387
2025 Q3	$184K	Buy	+45,941	New	+$145K	﹤0.01%	1398
2022 Q4	–	Sell	-369,386	Closed	-$1.78M	–	1588
2022 Q3	$1.78M	Buy	369,386 +230,194	+165%	+$1.67M	0.02%	845
2022 Q2	$1.11M	Buy	+139,192	New	+$1.32M	0.01%	1034
2020 Q4	–	Sell	-81,624	Closed	-$2.69M	–	1905
2020 Q3	$2.69M	Buy	81,624 +64,199	+368%	+$2.78M	0.05%	311
2020 Q2	$816K	Buy	+17,425	New	+$661K	0.02%	846

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ExodusPoint Capital Management's ADCT Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its ADC Therapeutics (ADCT) stake by 66% in Q1 2026, selling an estimated $148K and leaving 19,280 shares worth $72.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1452.

ExodusPoint Capital Management first reported a position in ADCT in Q2 2020 and has held it in 7 quarters since. The position peaked at $2.69M in Q3 2020. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

ExodusPoint Capital Management held 19,280 shares of ADC Therapeutics worth $72.3K as of Q1 2026.
ExodusPoint Capital Management sold 37,503 ADC Therapeutics shares in Q1 2026, an estimated $148K.
ADC Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1452 holding.
ExodusPoint Capital Management first reported a position in ADC Therapeutics in Q2 2020 and has held it in 7 quarters since.
ExodusPoint Capital Management's ADC Therapeutics position peaked at $2.69M in Q3 2020.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.